“Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1”

Yong L, Ma Y, et al. Phtyother. Res. 2019 May. This article shows that oleandrin enhances or synergizes with the standard of care chemotherapy agent cisplatin against osteosarcoma (bone) cancer. Importance: Phoenix Biotechnology’s drug PBI-05204 contains oleandrin as one of its main active ingredients and we have previously shown that it acts in a synergistic manner with chemotherapy drugs against a variety of different types of human malignant disease. New data being prepared for publication now shows the PBI-05204 is synergistic with Temozolamide and radiotherapy against glioblastoma, a difficult to treat form of brain cancer. READ ABSTRACT